Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials

References

• Danese S, Fiocchi C. Ulcerative colitis [Review]. N Engl J Med. 2011 Nov 3;365(18):1713–1725.
   PubMed Web of Science ®Google Scholar
• Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside [Review]. Gut. 2012 Jun;61(6):918–932.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn’s disease [Research support, non-U.S. Gov’t Review]. Lancet. 2012 Nov 3;380(9853):1590–1605.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, EV L Jr., Colombel JF, et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts [Review]. Inflamm Bowel Dis. 2011 Jan;17(1):471–478.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Clin Pract Gastroenterol Hepatol. 2018 Jan;15(1):39–49.
   Google Scholar
• Dowdell AS, Colgan SP. Metabolic host-microbiota interactions in autophagy and the pathogenesis of Inflammatory Bowel Disease (IBD). Pharmaceuticals (Basel). 2021 Jul 22;14(8):708–716.
   PubMedGoogle Scholar
• Moon W, Loftus EV Jr. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2016 Apr;43(8):863–883.
   PubMed Web of Science ®Google Scholar
• Parkes M. The genetics universe of Crohn’s disease and ulcerative colitis [Review]. Dig Dis. 2012;30(Suppl 1):78–81.
   PubMedGoogle Scholar
• Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives [Research SUPPORT, NON-U.S. Gov’t]. Gut. 2011 May;60(5):631–637.
   PubMed Web of Science ®Google Scholar
• Kaakoush NO, Day AS, Huinao KD, et al. Microbial dysbiosis in pediatric patients with Crohn’s disease. J Clin Microbiol. 2012 Oct;50(10):3258–3266.
   PubMed Web of Science ®Google Scholar
• Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s disease. Inflamm Bowel Dis. 2014 Jun;20(6):978–986.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis [clinical trial, phase III, multicenter study randomized controlled trial. research support, non-U.S. Gov’t]. N Engl J Med. 2013 Aug 22;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Danese S, Colombel JF, Peyrin-Biroulet L, et al. Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future. Aliment Pharmacol Ther. 2013 May;37(9):855–866.
   PubMed Web of Science ®Google Scholar
• Barre A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Apr;47(7):896–905.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019 Sep 26;381(13):1201–1214.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013 Jun 1;146(1):85–95.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013 Jun 13;146(1):96–109.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan B, Sandborn WJ, et al. Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active ulcerative colitis: results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. JCC. 2022;16(Supplement_1):i042–3.
   Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014 Feb;146(2):392–400.
   PubMed Web of Science ®Google Scholar
• Danese S. Adalimumab for ulcerative colitis: a little is better than none? [Comment]. Inflamm Bowel Dis. 2012 Apr;18(4):793–794.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016 Jan 7;7(1):e135.
   PubMed Web of Science ®Google Scholar
• Katsanos KH, Papamichael K, Feuerstein JD, et al. Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. Clin Immunol. 2018 Mar 12;206:9–14.
   PubMed Web of Science ®Google Scholar
• Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Mar;49(6):664–680.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn’s disease. BioDrugs. 2014 Dec 11;29:57–67.
   Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis [Clinical trial, phase II multicenter study randomized controlled trial research support, non-U.S. Gov’t]. N Engl J Med. 2012 Aug 16;367(7):616–624.
   PubMed Web of Science ®Google Scholar
• Weisshof R, Aharoni GM, Sossenheimer PH, et al. Real-world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci. 2019 Jul;64(7):1945–1951.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017 Jan 21;389(10066):266–275.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016 May 5;374(18):1754–1762.
   PubMed Web of Science ®Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):22–31
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G. Anti-TNF biosimilars in inflammatory bowel disease: searching the proper patient’s profile? Curr Med Chem. 2018 May 13;26(2):280–287.
   Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohn’s Colitis. 2017 Jan;11(1):26–34.
   Google Scholar
• Declerck P, Mellstedt H, Danese S. Biosimilars - terms of use. Curr Med Res Opin. 2015 Dec;31(12):2325–2330.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014 Jul;13(7):751–755.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Osterman MT. Biologic therapy for ulcerative colitis. Gastroenterol Clin North Am. 2020 Dec;49(4):717–729.
   PubMed Web of Science ®Google Scholar
• Bickston SJ, Behm BW, Tsoulis DJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis [meta-analysis review]. Cochrane Database Syst Rev. 2014;8:CD007571.
   PubMedGoogle Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis [multicenter study randomized controlled trial research support, non-U.S. Gov’t]. Gastroenterology. 2011 Oct;141(4):1194–1201.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Cesarini M, Danese S. Biological therapy for ulcerative colitis: what is after anti-TNF [Review]. Curr Drug Targets. 2011 Sep;12(10):1433–1439.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis. 2017 Jun 1;11(6):649–670.
   Google Scholar
• Petric Z, Goncalves J, Paixao P. Under the umbrella of clinical pharmacology: inflammatory bowel disease, infliximab and adalimumab, and a bridge to an era of biosimilars. Pharmaceutics. 2022 Aug 24;14:9.
   Web of Science ®Google Scholar
• Attauabi M, Hoglund C, Fassov J, et al. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol. 2021 Sep;56(9):1040–1048.
   PubMed Web of Science ®Google Scholar
• Attauabi M, Madsen GR, Bendtsen F, et al. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis. Dig Liver Dis. 2021 Dec 10;54(9):1168–1178.
   PubMedGoogle Scholar
• Lam MC, Bressler B. Vedolizumab for ulcerative colitis and Crohn’s disease: results and implications of GEMINI studies. Immunotherapy. 2014;6(9):963–971.
   PubMed Web of Science ®Google Scholar
• Rietdijk ST, D’Haens GR. Vedolizumab for the treatment of ulcerative colitis. Expert Rev Clin Pharmacol. 2014 Jul;7(4):423–430.
   PubMed Web of Science ®Google Scholar
• Chateau T, Bonovas S, Le Berre C, et al. Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review. J Crohn’s Colitis. 2019 Dec 10;13(12):1569–1577.
   Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV Jr., et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019 Sep 26;381(13):1215–1226.
   PubMed Web of Science ®Google Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.
   PubMedGoogle Scholar
• Sandborn WJ, Feagan BG, Loftus EV Jr., et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020 Jun;158(8):2123–2138 e8.
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 Jun 4;399(10341):2113–2128.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Popa CD, Nucera V, et al. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022 Mar;18(3):233–244.
   PubMed Web of Science ®Google Scholar
• Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021 Dec 22;71(10):1976–1987.
   Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV Jr., et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021 Jun 19;397(10292):2372–2384.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Magro F, Peyrin-Biroulet L, et al. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohn’s Colitis. 2022 Jun 24;16(5):835–844.
   Google Scholar
• Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021 Sep 30;385(14):1280–1291.
   PubMed Web of Science ®Google Scholar
• Al-Horani R, Spanudakis E, Hamad B. The market for ulcerative colitis. Nat Rev Drug Discov. 2022 Jan;21(1):15–16.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Osterman MT, Thorpe AJ, et al. Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):116–125 e5.
   PubMed Web of Science ®Google Scholar
• Gledhill T, Bodger K. New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biologics. 2013;7:123–130.
   PubMedGoogle Scholar
• Jovani M, Danese S. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells [Review]. Curr Drug Targets. 2013 Nov;14(12):1433–1443.
   PubMed Web of Science ®Google Scholar
• Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015 Apr 24;64:77–83.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease [Multicenter study research support, non-U.S. Gov’t]. Gastroenterology. 2010 Feb;138(2):463–468. quiz e10–1
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review [Review]. Gut. 2012 Nov;61(11):1619–1635.
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD [Research support, Non-U.S. Gov’t review]. Nat Clin Pract Gastroenterol Hepatol. 2010 Jan;7(1):15–29.
   Google Scholar
• Battat R, Duijvestein M, Guizzetti L, et al. Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Am J Gastroenterol. 2019 May;114(5):733–745.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010 Jan;94(1):115–133.
   PubMed Web of Science ®Google Scholar
• Hanzel J, Hulshoff MS, Grootjans J, et al. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol. 2022 May;18(5):513–524.
   PubMed Web of Science ®Google Scholar
• Degagne E, Saba JD. S1pping fire: sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin Exp Gastroenterol. 2014;7:205–214.
   PubMedGoogle Scholar
• Moorman CD, Sohn SJ, Phee H. Emerging therapeutics for immune tolerance: tolerogenic vaccines, T cell therapy, and IL-2 therapy. Front Immunol. 2021;12:657768.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Danese S, Leszczyszyn J, et al. Oral ritlecitinib and brepocitinib in patients with moderate to severe active ulcerative colitis: data from the VIBRATO umbrella study. JCC. 2022;20(Suppl 1):S1030–1.
   Google Scholar
• Danese S, Panaccione R, D’Haens G, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active ulcerative colitis: 12-week results from the Phase 2 LATTICE-UC study. JCC. 2022;16(Suppl. 1):i091–i092.
   Google Scholar
• Chen B, Zhong J, Li X, et al. Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study. Gastroenterology. 2022 Aug 10;163(6):1555–1568.
   PubMedGoogle Scholar
• https://wwwprnewswirecom/news-releases/theravance-biopharma-inc-announces-top-line-results-from-phase-2b-dose-finding-induction-study-of-izencitinib-in-patients-with-ulcerative-colitis-301360836html.
   Google Scholar
• Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020 Feb;158(3):550–561.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Chiorean M, Panes J, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohn’s Colitis. 2021 Jun 22;15(6):950–959.
   Google Scholar
• https://www.globenewswire.com/news-release/2022/05/03/2435049/0/en/Connect-Biopharma-Announces-Week-12-Top-Line-Results-from-Phase-2-CBP-307-Trial-in-Patients-with-Moderate-to-Severe-Ulcerative-Colitis.html.
   Google Scholar
• Radeke HH, Stein J, Van Assche G, et al. A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis. Inflamm Intest Dis. 2020 Nov;5(4):180–190.
   PubMedGoogle Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020 Feb;158(3):537–549 e10.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease. Gastroenterology. 2022 Feb;162(2):495–508.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):105–115 e14.
   PubMed Web of Science ®Google Scholar
• Dignass A, Rubin D, Bressler B, et al. The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: phase 2b QUASAR Study results through week 12. 2022. https://wwwecco-ibdeu/publications/congress-abstracts/item/op23-the-efficacy-and-safety-of-guselkumab-induction-therapy-in-patients-with-moderately-to-severely-active-ulcerative-colitis-phase-2b-quasar-study-results-through-week-12html.
   Google Scholar
• Danese S, Klopocka M, Scherl EJ, et al. Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2324–2332 e6.
   PubMed Web of Science ®Google Scholar
• https://de.style.yahoo.com/abivax-ver%C3%B6ffentlicht-hervorragende-einjahres-daten-160005527.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmRlLw&guce_referrer_sig=AQAAAAoA7XaZesyn9Ge6S-ifRvuCikgwPTU0yFkNQVGrXOzfAxwJd4nuJ8EbtmDxPhP9xxSO72aBgzxjPYoUWhozN8eLqFuR0neXE7_tkmeVhvnLzVPboEC3TR203yy6aB_vyd6RQelVlrvWQhKYD1fhO_XOr6K6f3GblTgYdNHi3YCe.
   Google Scholar
• Vermeire S, Hebuterne X, Tilg H, et al. Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase iia trial. Gastroenterology. 2021 Jun;160(7):2595–2598 e3.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Mattheakis LC, Modi NB, et al. PTG-100, an oral alpha4beta7 antagonist peptide: preclinical development and phase 1 and 2a studies in ulcerative colitis. Gastroenterology. 2021 Dec;161(6):1853–1864 e10.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015 Dec;149(7):1775–1783 e2.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Watanabe M, Ohmori T, et al. AJM300 (carotegrast methyl), an oral antagonist of alpha4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648–657.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology. 2019 Mar;156(4):946–957 e18.
   PubMed Web of Science ®Google Scholar
• Hibi T, Motoya S, Ashida T, et al. Efficacy and safety of abrilumab, an alpha4beta7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res. 2019 Jul;17(3):375–386.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Hart A, Bossuyt P, et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128–140.
   PubMed Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial [Clinical trial, phase II randomized controlled trial research support, non-U.S. Gov’t]. Lancet. 2014 Jul 26;384(9940):309–318.
   PubMed Web of Science ®Google Scholar
• Mayer L, Sandborn WJ, Stepanov Y, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2013 Mar 5;63(3):442–450.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Bhandari BR, Randall C, et al. Andecaliximab [anti-matrix metalloproteinase-9] induction therapy for ulcerative colitis: a randomised, double-blind, placebo-controlled, phase 2/3 study in patients with moderate to severe disease. J Crohn’s Colitis. 2018 Aug 29;12(9):1021–1029.
   Google Scholar
• Atreya R, Peyrin-Biroulet L, Klymenko A, et al. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1063–1075.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022 May;162(6):1650–1664 e8.
   PubMed Web of Science ®Google Scholar
• Al Khoury A, Balram B, Bessissow T, et al. Patient perspectives and expectations in inflammatory bowel disease: a systematic review. Dig Dis Sci. 2022 Jun;67(6):1956–1974.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient. 2013;6(4):241–255.
   PubMedGoogle Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014 Jan 27;12(9):1485–1493.
   PubMed Web of Science ®Google Scholar
• Cayatte C, Joyce-Shaikh B, Vega F, et al. Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease. Clin Transl Gastroenterol. 2012 Feb 16;3:e10.
   PubMed Web of Science ®Google Scholar
• Tew GW, Hackney JA, Gibbons D, et al. Association between response to etrolizumab and expression of integrin alphae and granzyme A in colon biopsies of patients with ulcerative colitis. Gastroenterology. 2016 Feb;150(2):477–87 e9.
   PubMed Web of Science ®Google Scholar
• Parigi TL, D’Amico F, Abreu MT, et al. Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 May;7(5):390–391.
   PubMed Web of Science ®Google Scholar